Literature DB >> 35430613

The complex karyotype in hematological malignancies: a comprehensive overview by the Francophone Group of Hematological Cytogenetics (GFCH).

F Nguyen-Khac1,2,3, A Bidet4, A Daudignon5, M Lafage-Pochitaloff6,7, G Ameye8, C Bilhou-Nabéra9, E Chapiro10,11,12, M A Collonge-Rame13, W Cuccuini14, N Douet-Guilbert15,16, V Eclache17, I Luquet18, L Michaux8, N Nadal19, D Penther20, B Quilichini21, C Terre22, C Lefebvre23, M-B Troadec15,16, L Véronèse24,25.   

Abstract

Karyotype complexity has major prognostic value in many malignancies. There is no consensus on the definition of a complex karyotype, and the prognostic impact of karyotype complexity differs from one disease to another. Due to the importance of the complex karyotype in the prognosis and treatment of several hematological diseases, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) has developed an up-to-date, practical document for helping cytogeneticists to assess complex karyotypes in these hematological disorders. The evaluation of karyotype complexity is challenging, and it would be useful to have a consensus method for counting the number of chromosomal abnormalities (CAs). Although it is not possible to establish a single prognostic threshold for the number of CAs in all malignancies, a specific consensus prognostic cut-off must be defined for each individual disease. In order to standardize current cytogenetic practices and apply a single denomination, we suggest defining a low complex karyotype as having 3 CAs, an intermediate complex karyotype as having 4 CAs, and a highly complex karyotype as having 5 or more CAs.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh：

Year:  2022        PMID： 35430613     DOI： 10.1038/s41375-022-01561-w

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


  143 in total

1.  Revised international prognostic scoring system for myelodysplastic syndromes.

Authors:  Peter L Greenberg; Heinz Tuechler; Julie Schanz; Guillermo Sanz; Guillermo Garcia-Manero; Francesc Solé; John M Bennett; David Bowen; Pierre Fenaux; Francois Dreyfus; Hagop Kantarjian; Andrea Kuendgen; Alessandro Levis; Luca Malcovati; Mario Cazzola; Jaroslav Cermak; Christa Fonatsch; Michelle M Le Beau; Marilyn L Slovak; Otto Krieger; Michael Luebbert; Jaroslaw Maciejewski; Silvia M M Magalhaes; Yasushi Miyazaki; Michael Pfeilstöcker; Mikkael Sekeres; Wolfgang R Sperr; Reinhard Stauder; Sudhir Tauro; Peter Valent; Teresa Vallespi; Arjan A van de Loosdrecht; Ulrich Germing; Detlef Haase
Journal:  Blood       Date:  2012-06-27       Impact factor: 22.113

2.  [Induced leukemias. Cytogenetical and cytological aspects. Comparison with primitive leukemias (author's transl)].

Authors:  R Berger; A Bernheim; M T Daniel; F Valensi; G Flandrin
Journal:  Nouv Rev Fr Hematol       Date:  1981

3.  Implementation of standardized international karyotype scoring practices is needed to provide uniform and systematic evaluation for patients with myelodysplastic syndrome using IPSS criteria: An International Working Group on MDS Cytogenetics Study.

Authors:  Kathy Chun; Anne Hagemeijer; Anwar Iqbal; Marilyn L Slovak
Journal:  Leuk Res       Date:  2009-08-07       Impact factor: 3.156

4.  Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype.

Authors:  Dimitri A Breems; Wim L J Van Putten; Georgine E De Greef; Shama L Van Zelderen-Bhola; Klasien B J Gerssen-Schoorl; Clemens H M Mellink; Aggie Nieuwint; Martine Jotterand; Anne Hagemeijer; H Berna Beverloo; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2008-08-11       Impact factor: 44.544

5.  Prognostic information from cytogenetic analysis in chronic B-lymphocytic leukemia and leukemic immunocytoma.

Authors:  G Juliusson; K H Robèrt; A Ost; K Friberg; P Biberfeld; B Nilsson; L Zech; G Gahrton
Journal:  Blood       Date:  1985-01       Impact factor: 22.113

6.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Authors:  Julie Schanz; Heinz Tüchler; Francesc Solé; Mar Mallo; Elisa Luño; José Cervera; Isabel Granada; Barbara Hildebrandt; Marilyn L Slovak; Kazuma Ohyashiki; Christian Steidl; Christa Fonatsch; Michael Pfeilstöcker; Thomas Nösslinger; Peter Valent; Aristoteles Giagounidis; Carlo Aul; Michael Lübbert; Reinhard Stauder; Otto Krieger; Guillermo Garcia-Manero; Stefan Faderl; Sherry Pierce; Michelle M Le Beau; John M Bennett; Peter Greenberg; Ulrich Germing; Detlef Haase
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

7.  Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes.

Authors:  J J Yunis; R E Rydell; M M Oken; M A Arnesen; M G Mayer; M Lobell
Journal:  Blood       Date:  1986-06       Impact factor: 22.113

8.  Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance.

Authors:  Julie Schanz; Francesc Solé; Mar Mallo; Elisa Luño; Jose Cervera; Isabel Granada; Barbara Hildebrandt; Marylin L Slovak; Kazuma Ohyashiki; Christa Fonatsch; Michael Pfeilstöcker; Thomas Nösslinger; Peter Valent; Aristoteles Giagounidis; Carlo Aul; Michael Lübbert; Reinhard Stauder; Otto Krieger; Michelle M Le Beau; John M Bennett; Peter Greenberg; Ulrich Germing; Detlef Haase
Journal:  Genes Chromosomes Cancer       Date:  2018-09-24       Impact factor: 5.006

9.  TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Authors:  Detlef Haase; Kristen E Stevenson; Donna Neuberg; Jaroslaw P Maciejewski; Aziz Nazha; Mikkael A Sekeres; Benjamin L Ebert; Guillermo Garcia-Manero; Claudia Haferlach; Torsten Haferlach; Wolfgang Kern; Seishi Ogawa; Yasunobu Nagata; Kenichi Yoshida; Timothy A Graubert; Matthew J Walter; Alan F List; Rami S Komrokji; Eric Padron; David Sallman; Elli Papaemmanuil; Peter J Campbell; Michael R Savona; Adam Seegmiller; Lionel Adès; Pierre Fenaux; Lee-Yung Shih; David Bowen; Michael J Groves; Sudhir Tauro; Michaela Fontenay; Olivier Kosmider; Michal Bar-Natan; David Steensma; Richard Stone; Michael Heuser; Felicitas Thol; Mario Cazzola; Luca Malcovati; Aly Karsan; Christina Ganster; Eva Hellström-Lindberg; Jacqueline Boultwood; Andrea Pellagatti; Valeria Santini; Lynn Quek; Paresh Vyas; Heinz Tüchler; Peter L Greenberg; Rafael Bejar
Journal:  Leukemia       Date:  2019-01-11       Impact factor: 12.883

10.  Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.

Authors:  A Kuendgen; M Nomdedeu; H Tuechler; G Garcia-Manero; R S Komrokji; M A Sekeres; M G Della Porta; M Cazzola; A E DeZern; G J Roboz; D P Steensma; A A Van de Loosdrecht; R F Schlenk; J Grau; X Calvo; S Blum; A Pereira; P Valent; D Costa; A Giagounidis; B Xicoy; H Döhner; U Platzbecker; C Pedro; M Lübbert; I Oiartzabal; M Díez-Campelo; M T Cedena; S Machherndl-Spandl; M López-Pavía; C D Baldus; M Martinez-de-Sola; R Stauder; B Merchan; A List; C Ganster; T Schroeder; M T Voso; M Pfeilstöcker; H Sill; B Hildebrandt; J Esteve; B Nomdedeu; F Cobo; R Haas; F Sole; U Germing; P L Greenberg; D Haase; G Sanz
Journal:  Leukemia       Date:  2020-06-29       Impact factor: 11.528
View more
  1 in total

Review 1.  Cytogenetic and Genetic Abnormalities with Diagnostic Value in Myelodysplastic Syndromes (MDS): Focus on the Pre-Messenger RNA Splicing Process.

Authors:  Nathalie Douet-Guilbert; Benoît Soubise; Delphine G Bernard; Marie-Bérengère Troadec
Journal:  Diagnostics (Basel)       Date:  2022-07-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.